Major depressive disorder

A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).   In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a significantly greater change in Montgomery-Åsberg Depression Rating Scale […]

The first subject has been dosed in a Phase I biomarker study of apimostinel, a rapid-acting N-methyl-D-aspartate receptor (NMDAR) modulator for major depressive disorders (MDD).  The injectable treatment was developed by clinical-stage biotechnology company Gate Neurosciences for acute depressive disorders such as postpartum and episodic depression, and depression with suicidality.  Apimostinel previously demonstrated proof-of-concept in […]

Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years?  MM: Although our understanding of the brain is still […]